Deprescribing Benzodiazepines in Older Patients: Impact of Interventions Targeting Physicians, Pharmacists, and Patients
The DOI matches its Crossref record; 159 of the 160 references it cites were found in a registry or an index.
Abstract
Benzodiazepines (BZDs; including the related Z-drugs) are frequently targets for deprescribing; long-term use in older people is harmful and often not beneficial. BZDs can result in significant harms, including falls, fractures, cognitive impairment, car crashes and a significant financial and legal burden to society. Deprescribing BZDs is problematic due to a complex interaction of drug, patient, physician and systematic barriers, including concern about a potentially distressing but rarely fatal withdrawal syndrome. Multiple studies have trialled interventions to deprescribe BZDs in older people and are discussed in this narrative review. Reported success rates of deprescribing BZD interventions range between 27 and 80%, and this variability can be attributed to heterogeneity of methodological approaches and limited generalisability to cognitively impaired patients. Interventions targeting the patient and/or carer include raising awareness (direct-to-consumer education, minimal interventions, and 'one-off' geriatrician counselling) and resourcing the patient (gradual dose reduction [GDR] with or without cognitive behavioural therapy, teaching relaxation techniques, and sleep hygiene). These are effective if the patient is motivated to cease and is not significantly cognitively impaired. Interventions targeted to physicians include prescribing interventions by audit, algorithm or medication review, and providing supervised GDR in combination with medication substitution. Pharmacists have less frequently been the targets for studies, but have key roles in several multifaceted interventions. Interventions are evaluated according to the Behaviour Change Wheel. Research supports trialling a stepwise approach in the cognitively intact older person, but having a low threshold to use less-consultative methods in patients with dementia. Several resources are available to support deprescribing of BZDs in clinical practice, including online protocols.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Issues related to switching to a longer-acting BZD are of particular concern in older adults, who may be at greater risk of medication-related harm because of age-related changes in pharmacokinetics and pharmacodynamics, such as reduced clearance of certain sedative–hypnotic medications and increased sensitivity to CNS effects.92,93”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [92]
In the citing paper
“Older adults’ decreased hepatic metabolism changes how the body processes and responds to medications, causing them to stay in the body longer and increasing the risk of adverse effects.92,93”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [92]
In the citing paper
“Fragmented care can be a barrier to effective BZD tapering because attitudes, knowledge, and conflicting advice from a patient’s medical teams (e.g., primary care, psychiatry, neurology, other specialty clinicians) and care partners can influence the BZD tapering process.92,169,170”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [92]
In the citing paper
“metabolic changes associated with aging make older adults more sensitive to BZDs, increasing their risk of adverse events such as cognitive impairment, particularly in the domains of memory, learning, attention, and visuospatial ability.92,171,172”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [92]
In the citing paper
“The focus of BZD deprescribing, especially among older adults, has become more prominent in Western and European nations especially in recent years given an aging demographic trend and the known risks of these agents in this population.163,164”
Citations
Cites
1 retracted
Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings
Denis, C., Fatseas, M., Lavie, E., & Auriacombe, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005194.pub2 · Cited by 122 · cited 3×
“Medications trialled include switching to long half-life BZDs such as diazepam or lormetazepam [43, 96]; antidepressants such as paroxetine [95, 135], imipramine [136] and trazodone [96]; hypnotics such as melatonin [93, 137]; b-blockers; and antiepileptics such as carbamazepine [138] and pregabalin [139].”
BackgroundRetractedMichie, S., van Stralen, M. M., & West, R. (2011) · Implementation Science · doi:10.1186/1748-5908-6-42 · Cited by 13,697 · cited 3×
“We have considered the role of Michie’s Behaviour Change Wheel [86] and the Behaviour Change Techniques Taxonomy (BCTT) Version 1 [87] in describing the interventions, and, using published methods, a single T a b le 2 S u m m ar y o f se le ct ed in te rv en ti o n s ta rg et ed at p at ie n ts to ce as e b en zo d ia…”
BackgroundMethodHoffmann, T. C., Glasziou, P. P., Boutron, I., Milne, R., Perera, R., Moher, D., Altman, D. G., Barbour, V., Macdonald, H., Johnston, M., et al. (2014) · BMJ · doi:10.1136/bmj.g1687 · Cited by 10,548
Michie, S., Richardson, M., Johnston, M., Abraham, C., Francis, J., Hardeman, W., Eccles, M. P., Cane, J., & Wood, C. E. (2013) · Annals of Behavioral Medicine · doi:10.1007/s12160-013-9486-6 · Cited by 7,629 · cited 4×
“Applying the BCTT [87] to an example minimal intervention letter [42] identified techniques 5.1 (information relating to health consequences), 5.6 (information relating to emotional consequences) and 4.1 (instruction on how to perform a behaviour).”
MethodInfluentialEncyclopedia of human behavior
(1994) · Choice Reviews Online · doi:10.5860/choice.32-0638 · Cited by 3,234
By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13702 · Cited by 2,609
STOPP/START criteria for potentially inappropriate prescribing in older people: version 2
O'Mahony, D., O'Sullivan, D., Byrne, S., O'Connor, M. N., Ryan, C., & Gallagher, P. (2014) · Age and Ageing · doi:10.1093/ageing/afu145 · Cited by 2,397
Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits
Glass, J., Lanctôt, K. L., Herrmann, N., Sproule, B. A., & Busto, U. E. (2005) · BMJ · doi:10.1136/bmj.38623.768588.47 · Cited by 1,161
Cumming, R. G., Salkeld, G., Thomas, M., & Szonyi, G. (2000) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/55.5.m299 · Cited by 896 · cited 1×
“Older people with low self-efficacy regarding falls prevention are prospectively associated with a higher risk of falling, lower functional activity, social participation and nursing home admission [56, 57].”
BackgroundReeve, E., Gnjidic, D., Long, J., & Hilmer, S. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12732 · Cited by 855 · cited 1×
“Deprescribing is defined as ‘‘the withdrawal of an inappropriate medication, supervised by a health care professional with the goal of managing polypharmacy and improving outcomes’’ [76].”
BackgroundSelf-citationAnderson, K., Stowasser, D., Freeman, C., & Scott, I. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-006544 · Cited by 725 · cited 1×
“These themes are validated in a wider review of potentially inappropriate medications and comments on the four main themes of awareness, inertia, self-efficacy and feasibility [143].”
BackgroundTannenbaum, C., Martin, P., Tamblyn, R., Benedetti, A., & Ahmed, S. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.949 · Cited by 665 · cited 7×
“The EMPOWER (Eliminating Medications through Patient Ownership of End Results) trial [80] was a pharmacy-based patient education programme that evaluated and demonstrated the significant efficacy of a direct-toolder-consumer booklet.”
BackgroundMethodInfluentialCognitive Effects of Long-Term Benzodiazepine Use: A Meta-Analysis
Barker, M. J., Greenwood, K. M., Jackson, M., & Crowe, S. F. (2004) · CNS Drugs · doi:10.2165/00023210-200418010-00004 · Cited by 552
Patient Barriers to and Enablers of Deprescribing: a Systematic Review
Reeve, E., To, J., Hendrix, I., Shakib, S., Roberts, M. S., & Wiese, M. D. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0106-8 · Cited by 536 · cited 1×
“A review of patient barriers and enablers to deprescribing emphasises the importance of a patient-centred deprescribing process [144].”
BackgroundGarfinkel, D., & Mangin, D. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.355 · Cited by 533 · cited 1×
“For example, among participants in a clinical trial of deprescribing, application of the Good Palliative-Geriatric Practice algorithm resulted in high rates of cessation of chronic BZD use in both geriatric medical inpatients [126] and community-dwelling adults [127].”
BackgroundIvers, N. M., Sales, A., Colquhoun, H., Michie, S., Foy, R., Francis, J. J., & Grimshaw, J. M. (2014) · Implementation Science · doi:10.1186/1748-5908-9-14 · Cited by 400 · cited 1×
“Repeated feedback cycles and specific goal setting are also supported [130].”
BackgroundWithdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines
Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M., & Sykora, K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610023151403 · Cited by 369
Brandt, J., & Leong, C. (2017) · Drugs in R&D · doi:10.1007/s40268-017-0207-7 · Cited by 356 · cited 2×
“Uncertainty exists over whether BZDs have a role in osteoporosis as GABAB receptors, which bind BZDs, have been identified in osteoblasts; however, this hypothesis has not been proven further and doubt is raised with the confounding factor of elderly women being at high risk of both osteoporosis and chronic BZD use [5…”
BackgroundMorin, C. M., Bastien, C., Guay, B., Radouco-Thomas, M., Leblanc, J., & Vallières, A. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.2.332 · Cited by 348 · cited 1×
“Another RCT comparing individual CBT, GDR, or a combination, in older patients with chronic insomnia showed those receiving both interventions were significantly more likely to cease post-intervention compared with either of the individual treatment arms [89].”
ResultPrevalence of Potentially Inappropriate Medication Use in Older Adults Using the 2012 Beers Criteria
Davidoff, A. J., Miller, G. E., Sarpong, E. M., Yang, E., Brandt, N., & Fick, D. M. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13320 · Cited by 344
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332 · cited 1×
“The risk of this withdrawal syndrome occurring starts after as little as 2 weeks of use [38], can last for months beyond cessation [39], and the onset of symptoms are generally predictable by the half-life of the drug [40, 41].”
BackgroundBenzodiazepines and Risk of Hip Fractures in Older People: A Review of the Evidence
Cumming, R. G., & Le Couteur, D. G. (2003) · CNS Drugs · doi:10.2165/00023210-200317110-00004 · Cited by 332 · cited 1×
“Several high-quality meta-analyses have shown an increased risk of hip fractures as a result of chronic BZD use of between 13 and 50%, attributable to approximately 10% of the total burden of hip fractures [47, 51, 52].”
BackgroundBenzodiazepine Use in Older Adults: Dangers, Management, and Alternative Therapies
Markota, M., Rummans, T. A., Bostwick, J. M., & Lapid, M. I. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.07.024 · Cited by 307 · cited 2×
“The withdrawal syndrome is usually characterised by a worsening of insomnia or anxiety symptoms (summarised in Table 1) and can lead to the erroneous conclusion that BZDs had a beneficial effect [35].”
BackgroundGarfinkel, D., Zur-Gil, S., & Ben-Israel, J. (2007) · PubMed · Cited by 262
Management of benzodiazepine misuse and dependence
Brett, J., & Murnion, B. (2015) · Australian Prescriber · doi:10.18773/austprescr.2015.055 · Cited by 260 · cited 4×
“BZDs are listed as medications of abuse [38] and can cause societal harms, such as using illegal means to obtain medications.”
BackgroundInfluentialWeich, S., Pearce, H. L., Croft, P., Singh, S., Crome, I., Bashford, J., & Frisher, M. (2014) · BMJ · doi:10.1136/bmj.g1996 · Cited by 259
Dassanayake, T., Michie, P., Carter, G., & Jones, A. (2011) · Drug Safety · doi:10.2165/11539050-000000000-00000 · Cited by 253 · cited 1×
“Another meta-analysis calculated that hypnotic use was associated with a 13% increased risk of being responsible for a car accident in the elderly, which is actually lower than among younger drivers, but it is unclear whether this effect is causative or confounded by lower doses in the elderly or more responsible driv…”
BackgroundAlbrecht, L., Archibald, M., Arseneau, D., & Scott, S. D. (2013) · Implementation Science · doi:10.1186/1748-5908-8-52 · Cited by 252
SCOPE: a scorecard for osteoporosis in Europe
Kanis, J. A., Borgström, F., Compston, J., Dreinhöfer, K., Nolte, E., Jonsson, L., Lems, W. F., McCloskey, E. V., Rizzoli, R., & Stenmark, J. (2013) · Archives of Osteoporosis · doi:10.1007/s11657-013-0144-1 · Cited by 246 · cited 1×
“5 million in the UK [73] by 2025; therefore, reduction of this risk is a significant public health issue.”
BackgroundGray, S. L., Dublin, S., Yu, O., Walker, R., Anderson, M., Hubbard, R. A., Crane, P. K., & Larson, E. B. (2016) · BMJ · doi:10.1136/bmj.i90 · Cited by 233 · cited 1×
“This has been extensively debated elsewhere [62–66] and although there is a strong association between chronic BZD use and dementia in observational studies [67], both experimental models and a large longitudinal prospective study are needed to answer the question of causality.”
BackgroundBenzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis
Donnelly, K., Bracchi, R., Hewitt, J., Routledge, P. A., & Carter, B. (2017) · PLOS ONE · doi:10.1371/journal.pone.0174730 · Cited by 225 · cited 2×
“Several high-quality meta-analyses have shown an increased risk of hip fractures as a result of chronic BZD use of between 13 and 50%, attributable to approximately 10% of the total burden of hip fractures [47, 51, 52].”
BackgroundIslam, M. M., Iqbal, U., Walther, B., Atique, S., Dubey, N. K., Nguyen, P.-A., Poly, T. N., Masud, J. H. B., Li, Y.-C. (., & Shabbir, S.-A. (2016) · Neuroepidemiology · doi:10.1159/000454881 · Cited by 218
Monane, M., Matthias, D. M., Nagle, B. A., & Kelly, M. A. (1998) · JAMA · doi:10.1001/jama.280.14.1249 · Cited by 216 · cited 2×
“Pharmacists have also successfully led minimal interventions in collaboration with family physicians [150], and have used computer-based alerts in a dispensing system to initiate discussion with family physicians, resulting in telephone contact with just over half of the physicians and a change to prescriptions of lon…”
BackgroundEffectiveness of current treatment approaches for benzodiazepine discontinuation: a meta‐analysis
Parr, J. M., Kavanagh, D. J., Cahill, L., Mitchell, G., & Young, R. M. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02364.x · Cited by 212 · cited 2×
“On current knowledge, a stepwise approach appears to be optimal for the individual, combining elements of the withdrawal strategies summarised in Box 1 [23, 140].”
BackgroundMethodDell’osso, B., & Lader, M. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2011.11.003 · Cited by 210 · cited 2×
“This risk is attributable to the effects BZDs have on the CNS, which are also risk factors for falls: psychomotor slowing, impaired balance and gait speed, muscle relaxation, blurred vision, sedation, and impaired cognition, including reduced attention, learning and anterograde amnesia [5].”
BackgroundOrgeta, V., Qazi, A., Spector, A., & Orrell, M. (2015) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.148130 · Cited by 207 · cited 1×
“CBT is shown to be effective and safe in older people with mild-tomoderate dementia, for the treatment of anxiety and insomnia [122, 123].”
BackgroundStrategies for discontinuing long-term benzodiazepine use: Meta-analysis
Voshaar, R. C. O., Couvée, J. E., Van Balkom, A. J. L. M., Mulder, P. G. H., & Zitman, F. G. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.189.3.213 · Cited by 205 · cited 4×
“On current knowledge, a stepwise approach appears to be optimal for the individual, combining elements of the withdrawal strategies summarised in Box 1 [23, 140].”
BackgroundMethodInfluentialVinkers, C. H., & Olivier, B. (2012) · Advances in Pharmacological Sciences · doi:10.1155/2012/416864 · Cited by 195
Osteoporosis costing all Australians: a new burden of disease analysis – 2012 to 2022
Watts, J. J., Abimanyi-Ochom, J., & Sanders, K. M. (2013) · Cited by 194
Reeve, E., Ong, M., Wu, A., Jansen, J., Petrovic, M., & Gnjidic, D. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2257-8 · Cited by 192
Long-term Therapeutic Use of Benzodiazepines: II. Effects of Gradual Taper
Schweizer, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220024003 · Cited by 191 · cited 3×
“The severity of distress during withdrawal is independent of the plasma half-life of BZD and is predominantly psychological: baseline personality, high levels of neuroticism, lower educational level, lower baseline quality of life, and, at high doses, low levels of social support are associated with increased distress…”
BackgroundCURRAN, H. V., COLLINS, R., FLETCHER, S., KEE, S. C. Y., WOODS, B., & ILIFFE, S. (2003) · Psychological Medicine · doi:10.1017/s0033291703008213 · Cited by 190 · cited 29×
“As BZD dependence and withdrawal has a large psychological component, attempts have been made to use psychological interventions, either alone or in combination with GDR, to improve deprescribing rates and sustainability.”
BackgroundInfluentialPhysicians’ perspectives on prescribing benzodiazepines for older adults: a qualitative study
Cook, J. M., Marshall, R., Masci, C., & Coyne, J. C. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-006-0021-3 · Cited by 178 · cited 1×
“Patients are more likely to cease when their doctor was both the initial prescriber and the initiating deprescriber [116], although physicians often underestimate this influence [120].”
BackgroundFarrell, B., Tsang, C., Raman-Wilms, L., Irving, H., Conklin, J., & Pottie, K. (2015) · PLOS ONE · doi:10.1371/journal.pone.0122246 · Cited by 178 · cited 1×
“A recent modified Delphi process concluded that BZDs are the top priority for the development of deprescribing guidelines due to clinicians needing assistance with negotiating changes with patients, finding nonpharmacologic approaches to manage symptoms, and managing the process of tapering [77].”
Background(2003) · Europe PMC (PubMed Central) · Cited by 176
Rissman, R. A., & Mobley, W. C. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07237.x · Cited by 172 · cited 2×
“Midazolam has also been shown to produce a greater potentiation of GABAmediated currents in neurons from aged rats than from young rats [34].”
BackgroundDrug Metabolism in Older People--A Key Consideration in Achieving Optimal Outcomes With Medicines
McLachlan, A. J., & Pont, L. G. (2012) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glr118 · Cited by 172 · cited 1×
“In the older person, impaired clearance of BZDs likely occurs due to both an increased volume of distribution because of a relative increase in total body fat and reduced hepatic clearance from impaired phase I and II pathways due to reduced hepatic blood flow and liver size [30, 31].”
BackgroundPimlott, N., Hux, J. E., Wilson, L., Kahan, M., Li, C., & Rosser, W. (2003) · Europe PMC (PubMed Central) · Cited by 166
Association between Benzodiazepine Use and Dementia: A Meta-Analysis
Zhong, G., Wang, Y., Zhang, Y., & Zhao, Y. (2015) · PLOS ONE · doi:10.1371/journal.pone.0127836 · Cited by 164
Treatment of xerostomia and hyposalivation in the elderly: A systematic review
Montoya, J. A. G., Silvestre, F., Barrios‐Rodríguez, R., & Silvestre‐Rangil, J. (2016) · Medicina oral, patología oral y cirugía bucal · doi:10.4317/medoral.20969 · Cited by 163 · cited 1×
“While not older-person-specific, evidence on using acupuncture in this group suggests that it is safe and has some effect in conditions such as insomnia [112], xerostomia [113] and peripheral osteoarthritis [114].”
BackgroundAcupuncture for peripheral joint osteoarthritis
Kwon, Y. D., Pittler, M. H., & Ernst, E. (2006) · Rheumatology · doi:10.1093/rheumatology/kel207 · Cited by 160
Association between use of benzodiazepines and risk of fractures: a meta-analysis
Xing, D., L., X., Ma, J. X., Wang, J., Yang, Y., & Chen, Y. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2446-y · Cited by 158
Usage of benzodiazepines: A review
Donoghue, J., & Lader, M. (2010) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651500903447810 · Cited by 156 · cited 1×
“2 Prevalence BZD use by older people remains high throughout the developed world [8].”
BackgroundGould, R. L., Coulson, M. C., Patel, N., Highton-Williamson, E., & Howard, R. J. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.126003 · Cited by 156 · cited 4×
“CBT has been the most successful and has modest support from the Cochrane review [106] and older-patientfocused meta-analyses [2, 3].”
BackgroundInfluentialVoshaar, R. C. O., Gorgels, W. J. M. J., Mol, A. J. J., Van Balkom, A. J. L. M., Van De Lisdonk, E. H., Breteler, M. H. M., Van Den Hoogen, J. M., & Zitman, F. G. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.6.498 · Cited by 154 · cited 2×
“In contrast, the previously mentioned two-part Dutch study of chronic BZD users did not find additional clinical or economic benefit when attending group CBT focusing on managing withdrawal symptoms when compared with GDR alone [100, 107].”
BackgroundResultConsequences of the 1989 New York State Triplicate Benzodiazepine Prescription Regulations
Weintraub, M. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470170080028 · Cited by 147 · cited 1×
“Stringent restrictions on BZD prescription in the 1980s resulted in higher rates of prescription of more harmful barbiturate medications [133].”
BackgroundThe Benzodiazepine–Dementia Disorders Link: Current State of Knowledge
Pariente, A., de Gage, S. B., Moore, N. D., & Bégaud, B. (2015) · CNS Drugs · doi:10.1007/s40263-015-0305-4 · Cited by 144
Bashir, K., King, M., & Ashworth, M. J. (1994) · Europe PMC (PubMed Central) · Cited by 143
Psychosocial interventions for benzodiazepine harmful use, abuse or dependence
Darker, C. D., Sweeney, B. P., Barry, J. M., Farrell, M. F., & Donnelly-Swift, E. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009652.pub2 · Cited by 142 · cited 1×
“CBT has been the most successful and has modest support from the Cochrane review [106] and older-patientfocused meta-analyses [2, 3].”
Free Drug Metabolic Clearance in Elderly People
Butler, J. M., & Begg, E. J. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847050-00002 · Cited by 137 · cited 2×
“The role of reduced protein binding of BZDs in the elderly has been debated and is unlikely to significantly contribute to reduced clearance in the older person [30].”
BackgroundIs there really a link between benzodiazepine use and the risk of dementia?
de Gage, S. B., Pariente, A., & Bégaud, B. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1014796 · Cited by 132
Long-term benzodiazepine use by elderly people living in the community
Jorm, A. F., Grayson, D. A., Creasey, H. M., Waite, L. M., & Broe, G. A. (2000) · Australian and New Zealand Journal of Public Health · doi:10.1111/j.1467-842x.2000.tb00715.x · Cited by 131
Sirdifield, C., Anthierens, S., Creupelandt, H., Chipchase, S. Y., Christiaens, T., & Siriwardena, A. N. (2013) · BMC Family Practice · doi:10.1186/1471-2296-14-191 · Cited by 131 · cited 1×
“Pressures existing around time (being a quick fix compared with addressing psychosocial issues), fear of loss of patients or recurrence of symptoms, and difficulty providing successful alternatives made initiating withdrawal difficult [142].”
BackgroundEvaluation of an easy, cost-effective strategy for cutting benzodiazepine use in general practice.
Cormack, M., Sweeney, K., Hughes-Jones, H., & Foot, G. A. (1994) · Europe PMC (PubMed Central) · Cited by 130
Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users
Baandrup, L., Ebdrup, B. H., Rasmussen, J. Ø., Lindschou, J., Gluud, C., & Glenthøj, B. Y. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011481.pub2 · Cited by 128 · cited 1×
“Furthermore, multiple meta-analyses and Cochrane reviews do not support their use [2, 23, 138, 140, 141].”
BackgroundFacilitation of Benzodiazepine Discontinuation by Melatonin: A New Clinical Approach
Garfinkel, D., Zisapel, N., Wainstein, J., & Laudon, M. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.20.2456 · Cited by 127 · cited 2×
“In the elderly population, modest evidence from small RCTs exists for melatonin [93, 137] and lormetazepam, and these are summarised in Table 4 [43, 96].”
BackgroundMugunthan, K., McGuire, T., & Glasziou, P. (2011) · British Journal of General Practice · doi:10.3399/bjgp11x593857 · Cited by 123 · cited 2×
“Studies of both residents in nursing homes and community-dwelling older people [79, 83, 84, 88–91] have reported statistically significant, although clinically small, improvements in measures of cognition, neuropsychological symptoms, balance, and overall quality of life after deprescribing of chronic BZD use, and a s…”
BackgroundVicens, C., Bejarano, F., Sempere, E., Mateu, C., Fiol, F., Socias, I., Aragonès, E., Palop, V., Beltran, J. L., Piñol, J. L., et al. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.134650 · Cited by 122 · cited 1×
“Selected patients can independently manage GDR by themselves if given written instructions, and are equally as successful as those who undergo supervised GDR, even out to 36 months [103, 104].”
BackgroundPharmacological interventions for benzodiazepine mono-dependence management in outpatient settings
Denis, C., Fatseas, M., Lavie, E., & Auriacombe, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005194.pub3 · Cited by 121
Cognitive improvement following benzodiazepine discontinuation in elderly nursing home residents
Salzman, C., Fisher, J., Nobel, K., Glassman, R., Wolfson, A., & Kelley, M. (1992) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.930070205 · Cited by 117 · cited 2×
“These effects were seen as little as 2–3 weeks after medication cessation [88].”
BackgroundDeprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review
Pollmann, A. S., Murphy, A. L., Bergman, J. C., & Gardner, D. M. (2015) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-015-0019-8 · Cited by 114
Cognitive–behavioural therapy for anxiety in dementia: pilot randomised controlled trial
Spector, A. E., Charlesworth, G. M., King, M., Lattimer, M., Sadek, S. A., Marston, L., Rehill, A., Hoe, J., Qazi, A., Knapp, M. R. J., et al. (2015) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.113.140087 · Cited by 112 · cited 1×
“Concerns around the low quality of evidence for treating anxiety within this group mean the results of a further RCT of CBT to treat anxiety in people with mild-to-moderate dementia are currently awaited to guide practice on this issue [124].”
BackgroundRickels, K., DeMartinis, N., García-España, F., Greenblatt, D. J., Mandos, L. A., & Rynn, M. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.12.1973 · Cited by 110 · cited 1×
“Medications trialled include switching to long half-life BZDs such as diazepam or lormetazepam [43, 96]; antidepressants such as paroxetine [95, 135], imipramine [136] and trazodone [96]; hypnotics such as melatonin [93, 137]; b-blockers; and antiepileptics such as carbamazepine [138] and pregabalin [139].”
BackgroundA realist evaluation of patients’ decisions to deprescribe in the EMPOWER trial
Martin, P., & Tannenbaum, C. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-015959 · Cited by 110 · cited 1×
“On a theoretical basis [97], it also increases patient’s perceived self-efficacy for tapering (capacity) and motivates and provides opportunity to discuss cessation with a health professional [97, 98].”
BackgroundGarzón, C. E. R., Guerrero, J. M., Aramburu, Ó., & Guzmán, T. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03324897 · Cited by 106 · cited 2×
“In the elderly population, modest evidence from small RCTs exists for melatonin [93, 137] and lormetazepam, and these are summarised in Table 4 [43, 96].”
BackgroundImplications of Altered Drug Disposition in the Elderly: Studies of Benzodiazepines
Greenblatt, D. J., Shader, R. I., & Harmatz, J. S. (1989) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1989.tb03246.x · Cited by 102 · cited 1×
“Increased CNS effects in older people, such as increasing sedation, psychomotor impairment and postural sway, have been described in both single- and multidose controlled trials and cohort studies in the clinical setting [32]; however, application of these results may be limited due to the use of subjective pharmacody…”
Benzodiazepines and risk of death: Results from two large cohort studies in France and UK
Palmaro, A., Dupouy, J., & Lapeyre‐Mestre, M. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.07.006 · Cited by 99
Westbury, J. L., Jackson, S., Gee, P. R., & Peterson, G. M. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209991128 · Cited by 98 · cited 1×
“Pharmacists have been involved in many of the interventions mentioned in this review, from direct-to-consumer awareness raising (EMPOWER) [80], to influencing prescribers by writing prescribing guidelines, and to providing prescribing interventions such as audit, education or medication review (RedUse) [148].”
BackgroundMortality associated with anxiolytic and hypnotic drugs—A systematic review and meta-analysis
Parsaik, A. K., Mascarenhas, S. S., Khosh-Chashm, D., Hashmi, A., John, V. P., Okusaga, O. O., & Singh, B. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415616695 · Cited by 98
Benzodiazepines and risk of all cause mortality in adults: cohort study
Patorno, E., Glynn, R. J., Levin, R., Lee, M. P., & Huybrechts, K. F. (2017) · BMJ · doi:10.1136/bmj.j2941 · Cited by 98 · cited 1×
“Concerns have been raised regarding the effect of residual confounding in these data sets and one study has tried to improve this with high-dimensional, propensity-matched cohorts [71]; however, this cohort only included patients initiating BZD, not chronic BZD users, therefore the effect of chronic BZD use on mortali…”
ResultYu, N.-W., Chen, P.-J., Tsai, H.-J., Huang, C.-W., Chiu, Y.-W., Tsay, W.-I., Hsu, J., & Chang, C.-M. (2017) · BMC Geriatrics · doi:10.1186/s12877-017-0530-4 · Cited by 97 · cited 1×
“However, it is clear that recent initiation or escalation of BZD dose and concurrent use of other centrally acting medications such as opiates or antidepressants increases the risk of falls and that using short half-life BZDs does not reduce the risk of falling [49, 52, 53].”
BackgroundMaust, D. T., Blow, F. C., Wiechers, I. R., Kales, H. C., & Marcus, S. C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m10713 · Cited by 93 · cited 2×
“There has not been an increase in new prescribing of BZDs in the older population, which means a significant proportion of chronic use is by the oldest patients [9].”
BackgroundO’Donnell, L. K., Gnjidic, D., Reeve, E., Chen, T. F., & Hilmer, S. N. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016652997 · Cited by 92 · cited 2×
“Patient-targeted strategies could help overcome these challenges [121].”
BackgroundSelf-citationBenzodiazepine dependence and withdrawal in elderly patients
Schweizer, E. E., CASE, W. G., & Rickels, K. (1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.4.529 · Cited by 91 · cited 1×
“The severity of distress during withdrawal is independent of the plasma half-life of BZD and is predominantly psychological: baseline personality, high levels of neuroticism, lower educational level, lower baseline quality of life, and, at high doses, low levels of social support are associated with increased distress…”
BackgroundMorin, C. M., Bélanger, L., Bastien, C., & Vallières, A. (2005) · Behaviour Research and Therapy · doi:10.1016/j.brat.2003.12.002 · Cited by 91 · cited 19×
“Concerns around the low quality of evidence for treating anxiety within this group mean the results of a further RCT of CBT to treat anxiety in people with mild-to-moderate dementia are currently awaited to guide practice on this issue [124].”
BackgroundInfluentialZitman, F. G., & Couvée, J. E. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.4.317 · Cited by 90 · cited 1×
“Medications trialled include switching to long half-life BZDs such as diazepam or lormetazepam [43, 96]; antidepressants such as paroxetine [95, 135], imipramine [136] and trazodone [96]; hypnotics such as melatonin [93, 137]; b-blockers; and antiepileptics such as carbamazepine [138] and pregabalin [139].”
BackgroundThe Costs of Benzodiazepine-Associated Hospital-Treated Fall Injuries in the EU: A Pharmo Study
Panneman, M. J. M., Goettsch, W., Kramarz, P., & Herings, R. M. C. (2003) · Drugs & Aging · doi:10.2165/00002512-200320110-00004 · Cited by 89 · cited 1×
“The majority of these costs were related to hip fractures [48].”
BackgroundChen, L., Bell, J. S., Visvanathan, R., Hilmer, S. N., Emery, T., Robson, L., Hughes, J. M., & Tan, E. C. K. (2016) · BMC Geriatrics · doi:10.1186/s12877-016-0363-6 · Cited by 87
Self-citationRisk versus risk: a review of benzodiazepine reduction in older adults
Paquin, A. M., Zimmerman, K., & Rudolph, J. L. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.925444 · Cited by 82 · cited 3×
“CBT has been the most successful and has modest support from the Cochrane review [106] and older-patientfocused meta-analyses [2, 3].”
BackgroundNo end in sight: benzodiazepine use in older adults in the United States.
Maust, D. T., Kales, H. C., Wiechers, I. R., Blow, F. C., & Olfson, M. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14379 · Cited by 82 · cited 1×
“The finding that only 16% of BZD prescriptions in older people have a mental health diagnosis associated with the prescription externally validates this measure of appropriateness [27].”
BackgroundBenzodiazepine use in Belgian nursing homes: a closer look into indications and dosages
Bourgeois, J., Elseviers, M. M., Azermai, M., Bortel, L. M. V., Petrović, M., & Stichele, R. V. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1188-z · Cited by 81 · cited 2×
“This is rare in the older person as most patients in this age group are taking therapeutic doses prescribed for them by their treating clinicians [24].”
BackgroundSirdifield, C., Chipchase, S. Y., Owen, S., & Siriwardena, A. N. (2017) · The Patient - Patient-Centered Outcomes Research · doi:10.1007/s40271-016-0182-z · Cited by 81 · cited 1×
“This area requires further investigation, particularly as the complex relationship between falls, fear of falling, BZD use, depression and anxiety is a patient barrier to deprescribing [59].”
BackgroundHeather, N., Bowie, A., Ashton, H., McAvoy, B., Spencer, I., Brodie, J., & Giddings, D. (2004) · Addiction Research & Theory · doi:10.1080/1606635310001634528 · Cited by 77 · cited 2×
“‘Minimal interventions’ consist of a letter from the patient’s general practitioner to patients identified as taking long-term BZDs, outlining concerns about chronic use and suggesting cessation or a gradual dose reduction (GDR) schedule [81, 83, 84].”
BackgroundSawan, M. J., Jeon, Y., Fois, R. A., & Chen, T. F. (2016) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2016.06.012 · Cited by 73 · cited 1×
“Finally, improving funding and addressing systematic issues such as workplace environment and organisational culture [146] may facilitate improved rates of cessation.”
BackgroundOptimizing sleep in older adults: Treating insomnia
Wennberg, A. M. V., Canham, S. L., Smith, M. T., & Spira, A. P. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.05.007 · Cited by 71 · cited 1×
“CBT is shown to be effective and safe in older people with mild-tomoderate dementia, for the treatment of anxiety and insomnia [122, 123].”
BackgroundIliffe, S., Curran, H. V., Collins, R., Yuen Kee, S. C., Fletcher, S., & Woods, B. (2004) · Aging & Mental Health · doi:10.1080/13607860410001669778 · Cited by 67 · cited 4×
“Fear of withdrawal is a major reason for patients and physicians to continue BZDs despite adverse events; this has been termed a ‘risk versus risk scenario’ [36, 37].”
BackgroundInfluentialMartin, P., Tamblyn, R., Ahmed, S., & Tannenbaum, C. (2013) · Patient Education and Counseling · doi:10.1016/j.pec.2013.02.016 · Cited by 66 · cited 1×
“On a theoretical basis [97], it also increases patient’s perceived self-efficacy for tapering (capacity) and motivates and provides opportunity to discuss cessation with a health professional [97, 98].”
BackgroundUse of benzodiazepines and related drugs in Manitoba: a population-based study
Alessi-Severini, S., Bolton, J. M., Enns, M. W., Dahl, M., Collins, D. M., Chateau, D., & Sareen, J. (2014) · CMAJ Open · doi:10.9778/cmajo.20130076 · Cited by 66 · cited 1×
“In developed countries, prescription rates of BZDs to the elderly appear to be reducing over time; however, the rates of prescription may be declining due to the substitution of perceived ‘safer alternatives’ (such as the aforementioned Z-drugs), rather than appropriate treatment [14, 15].”
BackgroundBallóková, A. L., Peel, N. M., Fialová, D., Scott, I. A., Gray, L., & Hubbard, R. E. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0159-3 · Cited by 64
Elliott, R. A., Woodward, M. C., & Oborne, C. A. (2001) · Internal Medicine Journal · doi:10.1046/j.1445-5994.2001.00139.x · Cited by 64 · cited 1×
“This resulted in small sustainable improvements in the appropriateness of BZD prescribing [129].”
BackgroundJohnson, C. F. A., Frei, C., Downes, N., McTaggart, S., & Akram, G. (2016) · British Journal of General Practice · doi:10.3399/bjgp16x685213 · Cited by 62 · cited 2×
“Recent estimates of prevalence in the older population have indicated a rate of approximately 8–12% in community-based studies from the US [9], New Zealand [10], Germany [11] and Scotland [12], with similar rates having been described in some developing countries such as Brazil (7.3% of community-dwelling older adults…”
BackgroundInfluentialSalonoja, M., Salminen, M., Aarnio, P., Vahlberg, T., & Kivela, S. L. (2010) · Age and Ageing · doi:10.1093/ageing/afp255 · Cited by 59 · cited 2×
“012) and a retrospective audit of an Australian falls clinic (75% compliance with deprescribing intervention) show successful cessation after this intervention [82, 102].”
BackgroundPek, E. A., Remfry, A., Pendrith, C., Fan‐Lun, C., Bhatia, R. S., & Soong, C. (2017) · Journal of Hospital Medicine · doi:10.12788/jhm.2739 · Cited by 59 · cited 1×
“Attempts to quantify the appropriateness of prescription have found that only 20–30% of BZD prescriptions are appropriate in the older person [21, 26].”
BackgroundBobes, J., Rubio, G., Terán, A., Cervera, G., López-Gómez, V., Vilardaga, I., & Pérez, M. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2010.12.004 · Cited by 57
Dollman, W. B., LeBlanc, V. T., Stevens, L., O'Connor, P. J., Roughead, E. E., & Gilbert, A. L. (2005) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2005.00674.x · Cited by 52 · cited 1×
“Unfortunately, a concurrent rise in antidepressants was noted, suggesting therapeutic substitution was occurring [154].”
BackgroundDionne, P.-A., Vasiliadis, H., Latimer, E. A., Berbiche, D., & Préville, M. (2012) · Psychiatric Services · doi:10.1176/appi.ps.201200089 · Cited by 51 · cited 1×
“In Canada, inappropriate prescriptions of BZDs are estimated to cost an extra CAN$3076 per person per year in hospitalisation, emergency department and outpatient visit costs [74].”
BackgroundCook, P. J., Huggett, A., Graham-Pole, R., Savage, I. T., & James, I. M. (1983) · BMJ · doi:10.1136/bmj.286.6359.100 · Cited by 49
Vicens, C., Sempere, E., Bejarano‐Romero, F., Socias, I. M., Mateu, C., Fiol, F., Palop, V., Mengual, M., Folch, S., Calatayud, G. L., et al. (2016) · British Journal of General Practice · doi:10.3399/bjgp16x683485 · Cited by 48 · cited 1×
“Selected patients can independently manage GDR by themselves if given written instructions, and are equally as successful as those who undergo supervised GDR, even out to 36 months [103, 104].”
Backgroundvan der Meulen, E., Zijlstra, G. A. R., Ambergen, T., & Kempen, G. I. J. M. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13083 · Cited by 45 · cited 1×
“Older people with low self-efficacy regarding falls prevention are prospectively associated with a higher risk of falling, lower functional activity, social participation and nursing home admission [56, 57].”
BackgroundSelf-Efficacy and Compliance With Benzodiazepine Taper in Older Adults With Chronic Insomnia.
Bélanger, L., Morin, C. M., Bastien, C., & Ladouceur, R. (2005) · Health Psychology · doi:10.1037/0278-6133.24.3.281 · Cited by 44 · cited 28×
“As BZD dependence and withdrawal has a large psychological component, attempts have been made to use psychological interventions, either alone or in combination with GDR, to improve deprescribing rates and sustainability.”
BackgroundMethodInfluentialNakao, M., Takeuchi, T., Nomura, K., Teramoto, T., & Yano, E. (2006) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2006.01565.x · Cited by 44 · cited 1×
“Medications trialled include switching to long half-life BZDs such as diazepam or lormetazepam [43, 96]; antidepressants such as paroxetine [95, 135], imipramine [136] and trazodone [96]; hypnotics such as melatonin [93, 137]; b-blockers; and antiepileptics such as carbamazepine [138] and pregabalin [139].”
BackgroundO'Connor, K. P., Marchand, A., Bélanger, L., Mainguy, N., Landry, P., Savard, P., Turcotte, J., Dupuis, G., Harel, F., & Lachance, L. (2004) · Addictive Behaviors · doi:10.1016/j.addbeh.2004.01.001 · Cited by 44 · cited 1×
“The severity of distress during withdrawal is independent of the plasma half-life of BZD and is predominantly psychological: baseline personality, high levels of neuroticism, lower educational level, lower baseline quality of life, and, at high doses, low levels of social support are associated with increased distress…”
BackgroundWestbury, J., Tichelaar, L., Peterson, G., Gee, P., & Jackson, S. (2011) · International Psychogeriatrics · doi:10.1017/s1041610211000421 · Cited by 44 · cited 1×
“homes to provide nonpharmacologic strategies for insomnia and anxiety compared with behavioural disturbance [149].”
BackgroundDiscontinuation of Long-Term Benzodiazepine Use: 10-Year Follow-Up
de Gier, N., Gorgels, W., Lucassen, P., Oude Voshaar, R., Mulder, J., & Zitman, F. (2011) · Family Practice · doi:10.1093/fampra/cmq113 · Cited by 43 · cited 1×
“8% remaining BZD abstinent at 10 years [100, 101].”
BackgroundPetrovic, M., Pevernagie, D., Mariman, A., Van Maele, G., & Afschrift, M. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0387-4 · Cited by 42 · cited 4×
“In the elderly population, modest evidence from small RCTs exists for melatonin [93, 137] and lormetazepam, and these are summarised in Table 4 [43, 96].”
BackgroundInfluentialA general population survey on patterns of benzodiazepine use and dependence in Lebanon
Naja, W. J., Pelissolo, A., Haddad, R. S., Baddoura, R., & Baddoura, C. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.102006429.x · Cited by 42 · cited 2×
“Increasing age is also a risk factor for chronic BZD use in developing countries such as Pakistan [17] and Lebanon [18], especially as access is easier without a prescription and access to medical services is not as readily available.”
BackgroundPeterson, J. F., Kripalani, S., Danciu, I., Harrell, D., Marvanova, M., Mixon, A. S., Rodriguez, C., & Powers, J. S. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13057 · Cited by 41
Martin, P., & Tannenbaum, C. (2017) · BMC Geriatrics · doi:10.1186/s12877-017-0432-5 · Cited by 41
Roth, T. G., Eklov, S., Drake, C. L., & Verster, J. C. (2013) · Traffic Injury Prevention · doi:10.1080/15389588.2013.830211 · Cited by 39 · cited 1×
“A meta-analysis of 14 randomised controlled trials (RCTs) concluded that driving performance was significantly impaired with longer half-life agents, higher doses, and when time between dose and driving was reduced [60].”
BackgroundSmith, A. J., & Tett, S. (2009) · Drugs & Aging · doi:10.2165/0002512-200926020-00003 · Cited by 39 · cited 1×
“In developed countries, prescription rates of BZDs to the elderly appear to be reducing over time; however, the rates of prescription may be declining due to the substitution of perceived ‘safer alternatives’ (such as the aforementioned Z-drugs), rather than appropriate treatment [14, 15].”
BackgroundGilbert, A., Innes, J. M., Owen, N., & Sansom, L. (1993) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1993.tb01433.x · Cited by 37 · cited 1×
“Teaching relaxation techniques to chronic BZD users in a single nursing home in combination with giving their family physicians and caregivers information on nonpharmacological management of sleep significantly reduced the proportion of BZD users [109].”
BackgroundTsunoda, K., Uchida, H., Suzuki, T., Watanabe, K., Yamashima, T., & Kashima, H. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2465 · Cited by 37 · cited 3×
“For instance, definitions of ‘elderly’ or ‘older’ ranges from C 40 years [78], living in a nursing home [79], to C 65 years [80].”
BackgroundBatty, G. M., Oborne, C. A., Swift, C. G., & Jackson, S. H. D. (2000) · International Journal of Geriatric Psychiatry · doi:10.1002/1099-1166(200010)15:10<892::aid-gps213>3.0.co;2-x · Cited by 35 · cited 1×
“Inpatient algorithms to assess the appropriateness of BZD indication in older inpatients were applied in the UK with only limited impact on prescribing [26, 128].”
MethodBenzodiazepine withdrawal in general practice.
(1982) · PubMed Central · Cited by 33
Kwok, T. C. Y., Leung, P., Wing, Y. K., Ip, I. N., Wong, B., Ho, D. W., Wong, & Ho, F. (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s45611 · Cited by 32 · cited 1×
“While not older-person-specific, evidence on using acupuncture in this group suggests that it is safe and has some effect in conditions such as insomnia [112], xerostomia [113] and peripheral osteoarthritis [114].”
BackgroundFurbish, S. M. L., Kroehl, M., Loeb, D. F., Lam, H. M., Lewis, C. L., Nelson, J., Chow, Z., & Trinkley, K. E. (2016) · Journal of Pharmacy Practice · doi:10.1177/0897190016660435 · Cited by 32 · cited 1×
“Family physicians referred to a single clinical pharmacist to facilitate the successful withdrawal or reduction of BZDs in just over half the 29 adult patients seen to date [153].”
BackgroundCouvée, J. E., & Zitman, F. G. (2002) · Addiction · doi:10.1046/j.1360-0443.2002.00081.x · Cited by 31 · cited 1×
“The risk of this withdrawal syndrome occurring starts after as little as 2 weeks of use [38], can last for months beyond cessation [39], and the onset of symptoms are generally predictable by the half-life of the drug [40, 41].”
BackgroundHypnosedative Use and Predictors of Successful Withdrawal in New Patients Attending a Falls Clinic
Joester, J., Vogler, C., Chang, K., & Hilmer, S. N. (2010) · Drugs & Aging · doi:10.2165/11584480-000000000-00000 · Cited by 28 · cited 2×
“012) and a retrospective audit of an Australian falls clinic (75% compliance with deprescribing intervention) show successful cessation after this intervention [82, 102].”
BackgroundSelf-citationEffect of Medicare Part D Benzodiazepine Exclusion on Psychotropic Use in Benzodiazepine Users
Ong, M. K., Xu, H., Zhang, L., Azocar, F., & Ettner, S. L. (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.04031.x · Cited by 26 · cited 1×
“In 2006, the removal of Medicaid reimbursements on BZDs for American nursing home residents lead to a 33% reduction in use; however, there was an increase in medication class switching, particularly to more expensive brand-name medications [134].”
BackgroundUncovering the source of new benzodiazepine prescriptions in community‐dwelling older adults’
Halme, A. S., Béland, S., Préville, M., & Tannenbaum, C. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3818 · Cited by 25 · cited 1×
“7-fold higher risk of chronic use compared with family physician-initiated BZDs [145].”
BackgroundAnalysis of benzodiazepine withdrawal program managed by primary care nurses in Spain
Lopez-Peig, C., Mundet, X., Casabella, B., del Val, J. L., Lacasta, D., & Diogene, E. (2012) · BMC Research Notes · doi:10.1186/1756-0500-5-684 · Cited by 25 · cited 1×
“The feasibility of supervised GDR is shown in cohort studies of community-dwelling patients, as summarised in Table 2 [90, 94].”
MethodTapering Off Benzodiazepines in Long-Term Users: An Economic Evaluation
Voshaar, R. C. O., Krabbe, P. F. M., Gorgels, W. J. M. J., Adang, E., van Balkom, A. J. L. M., van de Lisdonk, E. H., & Zitman, F. G. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624070-00007 · Cited by 23
Benzodiazepine abuse among the elderly
Sarkar, S., & Singh, S. (2016) · Journal of Geriatric Mental Health · doi:10.4103/2348-9995.195605 · Cited by 23 · cited 2×
“Clinicians should enquire about a history of substance abuse, personality disorders and psychiatric disorders when deciding to prescribe BZDs, and specialist advice should be sought if there is risk of diversion of BZDs [75].”
BackgroundBatty, G. M., Hooper, R., Oborne, C. A., & Jackson, S. H. (2001) · British Journal of Clinical Governance · doi:10.1108/14664100110408608 · Cited by 22 · cited 2×
“Attempts to quantify the appropriateness of prescription have found that only 20–30% of BZD prescriptions are appropriate in the older person [21, 26].”
BackgroundMethodIqbal, S. P., Ahmer, S., Farooq, S., Parpio, Y. N., Tharani, A. J., Khan, R. A., & Zaman, M. (2011) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/1747-597x-6-19 · Cited by 22 · cited 2×
“Increasing age is also a risk factor for chronic BZD use in developing countries such as Pakistan [17] and Lebanon [18], especially as access is easier without a prescription and access to medical services is not as readily available.”
BackgroundDiscontinuing Benzodiazepine Therapy: An Interdisciplinary Approach at a Geriatric Day Hospital
Chen, L., Farrell, B. J., Ward, N. M., Russell, G. M., Eisener-Parsche, P., & Dore, N. L. (2010) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.3821/1913-701x-143.6.286 · Cited by 22 · cited 3×
“Consideration could be given to using other clinicians, such as pharmacists, nurses or social workers, to provide psychological support [115].”
BackgroundAddressing the Issue of Chronic, Inappropriate Benzodiazepine Use: How Can Pharmacists Play a Role?
Gallagher, H. C. (2013) · Pharmacy · doi:10.3390/pharmacy1020065 · Cited by 21
Perceptions of Benzodiazepine Dependence Among Women Age 65 and Older
Canham, S. L., Gallo, J., & Simoni-Wastila, L. (2014) · Journal of Gerontological Social Work · doi:10.1080/01634372.2014.901470 · Cited by 21 · cited 4×
“Fear of withdrawal is a major reason for patients and physicians to continue BZDs despite adverse events; this has been termed a ‘risk versus risk scenario’ [36, 37].”
BackgroundInfluentialAcceptability of cognitive‐behaviour therapy via the Internet for cessation of benzodiazepine use
PARR, J. M., KAVANAGH, D. J., YOUNG, R. M., & MITCHELL, G. (2011) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2010.00183.x · Cited by 20 · cited 1×
“A small pilot study has also investigated providing CBT sessions over the internet but did not specifically involve older people [110].”
BackgroundBarros, G. H., Caldeira, M. H., Araujo, L. M., Cendoroglo, M. S., & Almada-Filho, C. M. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14915 · Cited by 20
van de Steeg-van Gompel, C. H. P. A., Wensing, M., & De Smet, P. A. G. M. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.07.009 · Cited by 19 · cited 1×
“This is best exemplified by an unsuccessful study of community pharmacy-led minimal intervention where the key limitation was family physician cooperation in returning clinical information, limiting the number of intervention letters sent [152].”
BackgroundFond, G. B., Fajula, C., Dassa, D., Brunel, L., Lançon, C., & Boyer, L. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4312-z · Cited by 19
An intervention to improve benzodiazepine use--a new approach
Smith, A. J., & Tett, S. E. (2010) · Family Practice · doi:10.1093/fampra/cmq007 · Cited by 18 · cited 1×
“This significantly reduced the number of nursing home residents taking chronic BZDs for C 6 months; however, overall BZD use did not change compared with controls, or post-intervention, despite good use and retention of the tool’s key messages [155].”
BackgroundThe Role of Craving in Relapse After Discontinuation of Long-Term Benzodiazepine Use
Mol, A. J. J., & Voshaar, R. C. O. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1209 · Cited by 18 · cited 2×
“Equally, relapse is predicted by the level of psychological distress after intervention, including insomnia severity, somatisation [108], or more severe craving symptoms [118].”
BackgroundVariation in benzodiazepine and antipsychotic use in people aged 65 years and over in New Zealand.
Jackson, G., Gerard, C., Minko, N., & Parsotam, N. (2014) · PubMed · Cited by 17
Vaapio, S., Puustinen, J., Salminen, M. J., Vahlberg, T. J., Salonoja, M., Lyles, A., & Kivelä, S.-L. (2015) · International journal of gerontology · doi:10.1016/j.ijge.2014.03.009 · Cited by 17
Benzodiazepine Initiation and Dose Escalation
Skinner, B. W., Johnston, E. V., & Saum, L. M. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016682530 · Cited by 17 · cited 1×
“However, it is clear that recent initiation or escalation of BZD dose and concurrent use of other centrally acting medications such as opiates or antidepressants increases the risk of falls and that using short half-life BZDs does not reduce the risk of falling [49, 52, 53].”
BackgroundSystemic model of chronic benzodiazepine use among mature adults
Pérodeau, G., Grenon, É., Grenier, S., & O’Connor, K. P. (2015) · Aging & Mental Health · doi:10.1080/13607863.2015.1015961 · Cited by 16 · cited 1×
“A broad and sophisticated biopsychosocial model of chronic use has been described using grounded theory analysis [46].”
MethodClinical Pharmacokinetics and Pharmacodynamics of Anxiolytics and Sedative/Hypnotics
DeVane, C. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-27883-4_10 · Cited by 16
Yokoi, Y., Misal, M., Oh, E. S., Bellantoni, M. F., & Rosenberg, P. B. (2013) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.12113 · Cited by 13 · cited 2×
“The dementia subgroup has been examined in a retrospective audit of a chronic medical/psychiatric unit, which reported no difference in clinical outcomes between patients who ceased BZD and those who did not [105].”
BackgroundHeather, N., Paton, J., & Ashton, H. (2011) · Addiction Research & Theory · doi:10.3109/16066359.2011.569102 · Cited by 12 · cited 2×
“Patients are more likely to cease when their doctor was both the initial prescriber and the initiating deprescriber [116], although physicians often underestimate this influence [120].”
BackgroundMethodPharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users
Baandrup, L., Ebdrup, B. H., Lindschou, J., Gluud, C. N., & Glenthoj, B. Y. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011481 · Cited by 12
Patterns of chronic benzodiazepine use in the elderly
Sgnaolin, V., Engroff, P., Andrade, C. P., Loureiro, F., Nogueira, E. L., Cataldo Neto, A., & Gomes, I. (2016) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/0101-60830000000089 · Cited by 11 · cited 1×
“3% of community-dwelling older adults) [13].”
Mell, T., Jacob, L., Fuhr, I., Dick, S., Rapp, M. A., & Kostev, K. (2017) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp202904 · Cited by 10
Williams, F., Mahfouz, C., Bonney, A. D., Pearson, R., Seidel, B. M., Dijkmans-Hadley, B. R., & Ivers, R. G. (2016) · PubMed · Cited by 9
Yeung, W., Chung, K., Zhang, Z.-J., Chan, W. C., Zhang, S., Ng, R. M.-K., Chan, C. L.-W., Ho, L., Yu, B. Y., & Lao, L. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-1692-5 · Cited by 9 · cited 1×
“An RCT protocol has recently been published to compare electroacupuncture, in combination with GDR, with GDR alone [111].”
MethodChung, K. (1997) · PubMed · Cited by 6
Gonzalez-Salvador (1999) · doi:10.1002/(sici)1099-1166(199909)14:9
Research works printed but not linked: 3
- Hatton J. Fear of falling and its relationship to depression and anxiety in older adults living in the community and in extended care facilities in Australia [professional Doctorate]. Perth: Murdoch University; 2016.
- Petrovic M, Pevernagie D, Van Den Noortgate N, Mariman A, Michielsen W, Afschrift M. A program for short-term withdrawal from benzodiazepines in geriatric hospital inpatients: Success rate and effect on subjective sleep quality. Int J Geriatr Psychiatry. 1999;14(9):754–60. · doi:10.1002/(sici)1099-1166(199909)14:9<754::aid-gps15>3.0.co;2-e
- Towle I, Adams J. A novel, pharmacist-led strategy to reduce the prescribing of benzodiazepines in Paisley. Pharm J. 2006;276(7386):136–8.
Cited by
Deprescribing in older adults with polypharmacy
Hung, A., Kim, Y. H., & Pavon, J. M. (2024) · BMJ · doi:10.1136/bmj-2023-074892 · Cited by 174
“38 39 Implementation strategies Overcoming these barriers is paramount for successful deprescribing, and implementation science can offer valuable tools and strategies.”
BackgroundBrandt, J., Bressi, J., Lê, M.-L., Neal, D., Cadogan, C., Witt-Doerring, J., Witt-Doerring, M., & Wright, S. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102507 · Cited by 77
“163,164 Barriers and enablers of BZD deprescribing success are being increasingly understood from the exploration of the patient and pre-scriber experiences.”
BackgroundLynch, T., Ryan, C., Hughes, C. M., Presseau, J., van Allen, Z. M., Bradley, C. P., & Cadogan, C. A. (2020) · Addiction · doi:10.1111/add.14981 · Cited by 76
“This is concerning, as age-related physiological changes impact on the drugs’ pharmacokinetics and pharmacodynamics, therebymakingolder adults most susceptible to BZRAs’ adverse effects such as falls, fractures and cognitive impairment [21,22].”
BackgroundCapiau, A., Huys, L., van Poelgeest, E. P., van der Velde, N., Petrović, M., Somers, A., & the EuGMS Task, F. G. O. F. (2022) · European Geriatric Medicine · doi:10.1007/s41999-022-00731-4 · Cited by 94
“Deprescribing is challenging, because patients and physicians are often reluctant out of fear for the potential risk of the withdrawal syndrome [80].”
BackgroundTorres-Bondia, F., de Batlle, J., Galván, L., Buti, M., Barbé, F., & Piñol-Ripoll, G. (2020) · BMC Public Health · doi:10.1186/s12889-020-08984-z · Cited by 69
Metadata
- Authors
- Ng, B. J., Le Couteur, D. G., & Hilmer, S. N.
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- Hilmer, Sarah N.
- Venue
- Drugs & Aging
- Published
- 2018-04-28
- Volume
- 35
- Issue
- 6
- Pages
- 493-521
- ISSN
- 1170-229X (ISSN-L)
- 1179-1969
- OpenAlex
- W2800093210
- Cited by
- 118
- References
- 160
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 13 · 2023: 14 · 2022: 23 · 2021: 22 · 2020: 11 · 2019: 14 · 2018: 2
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Drugs & Aging (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ageing and Alzheimers Institute
- Penney Ageing Research Unit
- New South Wales Health Translational Research Grants Scheme (TRG274)
- Australian and New Zealand Society for Geriatric Medicine
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- benzodiazepine deprescribing, older adults, Z-drugs, gradual dose reduction, cognitive behavioral therapy, sleep hygiene, prescribing interventions, pharmacist intervention, medication review, Behaviour Change Wheel, dementia, withdrawal syndrome, falls and fractures, cognitive impairment
- MeSH terms
- Deprescriptions, Age Factors, Attitude of Health Personnel, Benzodiazepines, Geriatrics, Humans, Pharmacists, Physicians, Drug Prescriptions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.